Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

UCB's Rheumatoid Arthritis Treatment Approved for China

publication date: Jul 24, 2019

Belgium's UCB was granted a China license to import Cimzia®, a biologic drug, to China for patients with moderate-to-severe rheumatoid arthritis. China's NMPA granted the approval following a priority review. Cimzia is an anti-TNF biologic with a unique Fc-free molecular structure. In the Phase III trial, it was administered in combination with methotrexate and compared to methotrexate alone. To promote Cimzia, UCB will partner with Cinkate, a US-China pharma that already markets a disease modifying anti-rheumatic drug, leflunomide, in China. More details....

Stock Symbol: (Euronext: UCB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.